BSX生命科学与高端医疗● Live Quotes Active

Boston Scientific Corporation

No mega hedge funds in our coverage currently report a major 13F position in this stock

Live Price
24h Change
Mega Funds Holding
0/ 33 funds

Coverage: 0.0%

Avg Portfolio Weight
0%

-

Wall St Sentiment
0%Bullish
+0/0/-0
Total Tracked Shares
0shares

Based on SEC 13F filings

SGDC Dual-Core EngineSuper-Growth Dual-Core Radar

🚀BSX SGDC Quant Rating & Setup

Open SGDC Screener↗
4P Grade
B 级(70分)
RS Rating
20/ 99
Pattern Setup
Base Setup
Pivot Benchmark
$46.16Support: $42.70

📌 Business Moat Summary:Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

ℹ️
13F Hedge Fund Coverage NoticeNone of the 33 tracked mega hedge funds (e.g., Berkshire Hathaway, Bridgewater, Renaissance, Citadel) currently report a major 13F position in BSX.✦ Note: This stock is actively tracked by the SGDC Super-Growth Quant Engine (4P Grade B, RS Rating 20).

📈8-Quarter Institutional Ownership Evolution

Historical trajectory of institutional holders and allocation weight across the last 8 quarters

Select Quarter:
0% 均仓
0 f2026 Q2
0% 均仓
0 f2026 Q1
0% 均仓
0 f2025 Q4
0% 均仓
0 f2025 Q3
0% 均仓
0 f2025 Q2
0% 均仓
0 f2025 Q1
0% 均仓
0 f2024 Q4
0% 均仓
0 f2024 Q3
2026 Q2|Report Date: 2026-06-30
Holding Funds: 0 家Total Shares: 0Avg Weight: 0%

🏛️Institutional Investors Holding this Stock

Examine each hedge fund holding this ticker, weight, shares, and recent action

Sort by:
Manager / FundFund AUMWeightShares HeldActionAction
No tracked mega hedge funds currently hold this stock.
🎯

Want to see Wall Street's Top 50 Consensus Buys?

Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.

Go to Consensus Screener →

⚡Planning to trade BSX?

Add this symbol to your private journal or dividend tracker to monitor institutional moves.

BSX (Boston Scientific Corporation) Institutional 13F Ownership & SGDC Growth Analysis 2026 | WhaleTracker